JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


Anesth Analg 2009; 109:793-800
© 2009 International Anesthesia Research Society
doi: 10.1213/ane.0b013e3181adc384
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ohta, N.
Right arrow Articles by Fujino, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohta, N.
Right arrow Articles by Fujino, Y.
Related Collections
Right arrow Mechanisms
Right arrow Inflammation
Right arrow Preclinical Pharmacology
Right arrow Pharmacology


ANESTHETIC PHARMACOLOGY

Ketamine Inhibits Maturation of Bone Marrow-Derived Dendritic Cells and Priming of the Th1-Type Immune Response

Noriyuki Ohta, MD, PhD, Yoshifumi Ohashi, MD, and Yuji Fujino, MD, PhD

From the Intensive Care Unit, Osaka University Hospital, Osaka, Japan.

Address correspondence and reprint requests to Noriyuki Ohta, MD, PhD, 2-15 Yamadaoka, Suita, Osaka, Japan. Address e-mail to nohta753{at}hp-icu.med.osaka-u.ac.jp.

BACKGROUND: Dendritic cells (DCs) play a key role as antigen-presenting cells and growing evidence suggests that DCs influence T-cell activation and regulate the polarity of the immune response. Ketamine has been reported to have immunomodulatory properties that affect immune cells, including macrophages and natural killer cells. However, the effect of ketamine on DCs has not been characterized. We examined the immunomodulation of DCs by ketamine.

METHODS: We used bone marrow-derived DCs induced by granulocyte–monocyte-colony stimulating factor and interleukin (IL)-4 from bone marrow and analyzed the expression of costimulatory molecules (CD40, CD80, and CD86), major histocompatibility complex class II molecules, and secretion of IL-12p40. Furthermore, we evaluated the immune response in mixed cell cultures of DCs and T cells and the contact hypersensitivity response in a whole animal.

RESULTS: Ketamine suppressed the expression of CD40, CD80, and major histocompatibility complex class II molecules in DCs. DCs treated with ketamine also secreted less IL-12p40 and displayed greater endocytosis. In mixed cell cultures with CD4+ T cells and DCs, ketamine-treated DCs showed less propensity to stimulate the proliferation of CD4+ T cells and the secretion of interferon from CD4+ T cells. Furthermore, ketamine-treated DCs impaired the induction of a cell-mediated immune response.

CONCLUSION: Our findings suggest that ketamine inhibits the functional maturation of DCs and interferes with DC induction of Th1 immunity in the whole animal. These novel findings provide new insight into the immunopharmacological role of ketamine.







Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2009 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2009 by the International Anesthesia Research Society.